Validation of scoring system for diagnosis of autoimmune hepatitis

Digestive Diseases and Sciences

Volumn 41, Issue 2, 1996, Pages 305-314

  Czaja, Albert J ^a   Carpenter, Herschel A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune hepatitis; Diagnosis; Scoring system

Indexed keywords

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; FEMALE; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AUTOIMMUNE DISEASES; BIOPSY; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEPATITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MIDDLE AGED; PREDNISONE; REPRODUCIBILITY OF RESULTS;

EID: 0029917789     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02093820     Document Type: Article

References (49)

1. Czaja AJ: Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 4:1-12, 1984
2. Czaja AJ: Autoimmune hepatitis: Current therapeutic concepts. Clin Immunother 1:413-424, 1994
3. Czaja AJ: Diagnosis and treatment of chronic hepatitis. Compr Ther 10:58-63, 1984
4. Czaja AJ: Autoimmune chronic active hepatitis - a specific entity? The negative argument. J Gastro-Hepatol 5:343-351, 1990
5. Kenny RP, Czaja AJ, Ludwig J, Dickson ER: Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 31:705-711, 1986
6. Czaja AJ, Carpenter HA, Manns MP: Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 105:1522-1528, 1993
7. Esteban JI, Esteban R, Viladomiu L, Lopez-Talavera JC, Gonzalez A, Hernandez JM, Roget M, Vargas V, Guardia J, Houghton M, Choo Q-L, Kuo G: Hepatitis C virus antibodies among risk groups in Spain. Lancet 2:294-297, 1989
8. Magrin S, Craxi A, Fiorentino G, Fabiano C, Provenzano G, Pinzello GB, Palzzo U, Almasio P, Pagliaro L: Is autoimmune chronic active hepatitis a HCV-related disease? J Hepatol 13:56-60, 1991
9. McFarlane IG, Smith HM, Johnson PJ, Bray GP, Vergani D, Williams R: Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive result? Lancet 335:754-757, 1990
10. Czaja AJ, Taswell HF, Rakela J, Schimek C: Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. Mayo Clin Proc 66:572-582, 1991
11. Mitchel LS, Jeffers LJ, Reddy KR, Cheinquer H, Coelho-Little E, Moreda R, Parker T, Silva M, Li XM, deMedina M, Coelho-Borges S, Hill M, Altman R, Manns MP, Schiff ER: Detection of hepatitis C virus antibody by first and second generation assays and polymerase chain reaction in patients with autoimmune chronic active hepatitis types I, II, and III. Am J Gastroenterol 88:1027-1034, 1993
12. Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, Pagliaro L: Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci 40:33-40, 1995
13. Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH: Manifestations of nonsuppurative cholangitis in chronic hepatobiliary disease: Morphologic spectrum, clinical correlations and terminology. Liver 4:105-116, 1984
14. Bach N, Thung SN, Schaffner F: The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis. Hepatology 15:572-577, 1992
15. Czaja AJ, Carpenter HA: Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824-1832, 1993
16. Cooksley WG, Powell LW, Kerr JF, Bhathal PS: Cholestasis in active chronic hepatitis. Am J Dig Dis 17:495-504, 1972
17. Crapper RM, Bhathal PS, Mackay IR, Frazer IH: "Acute" autoimmune hepatitis. Digestion 34:216-225, 1986
18. Czaja AJ, Rakela J, Ludwig J: Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 95:448-453, 1988
19. Amontree JS, Stuart TD, Bredfeldt JE: Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol 11:303-307, 1989
20. Nikias GA, Batts KP, Czaja AJ: The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 21:866-871, 1994
21. Czaja AJ, Nishioka M, Morshed SA, Hachiya T: Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 107:200-207, 1994
22. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF: Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 83:1066-1072, 1989
23. Czaja AJ, Manns MP, Homburger HA: Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103:1290-1295, 1992
24. Yamamoto AM, Cresteil D, Homberg JC, Alvarerz F: Characterization of the anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 104:1762-1767, 1993
25. Treichel U, Poralla T, Hess G, Manns M, Meyer zum Buschefelde K-H: Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology 11:606-612, 1990
26. Poralla T, Treichel U, Lohr H, Fleischer B: The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis 11:215-222, 1991
27. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde K-H: Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1:292-294, 1987
28. Wachter B, Kyriatsoulis A, Lohse AW, Gerken G, Meyer zum Buschenfelde K-H, Manns M: Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies. J Hepatol 11:232-239, 1990
29. Stechemesser E, Klein R, Berg PA: Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 18:1-9, 1993
30. Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg J-C: Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 8:1662-1666, 1988
31. Abuaf N, Johanet C, Chretien P, Martini E, Soulier E, Laperche S, Homberg JC: Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 6:892-898, 1992
32. Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH: Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci 37:1606-1611, 1992
33. Perdigoto R, Carpenter HA, Czaja AJ: Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 14:325-331, 1992
34. Czaja AJ, Hay JE, Rakela J: Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc 65:23-30, 1990
35. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA: The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 104:1755-1761, 1993
36. Czaja AJ: Chronic active hepatitis: The challenge for a new nomenclature. Ann Intern Med 119:510-517, 1993
37. Johnson PJ, McFarlane IG, Alvarez F, Bianchi FB, Bianchi L, Burroughs A, Chapman RW, Czaja AJ, Desmet V, Eddleston ALWF, Gerber MA, Hoofnagle JH, Kakumu S, MacSween RNM, Maddrey WC, Manns MP, Meyer zum Buschenfelde K-H, Mieli-Vergani G, Portmann BC, Reed WD, Schalm SW, Scheuer PJ, Toda G, Tsuji T, Tygstrup N, Vergani G, Zeniya M: Meeting report. International Autoimmune Hepatitis Group. Hepatology 18:998-1005, 1993
38. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513-1520, 1994
39. Ludwig J, Members of the Working Party of the World Congresses of Gastroenterology: Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver: Summary of recommendations developed by an international working party, supported by the World Congress of Gastroenterology, Los Angeles. 1994. Am J Gastroenterol 89:S177-S181, 1994
40. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF: Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 85:713-717, 1983
41. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 18:816-822, 1993
42. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105:1502-1507, 1993
43. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH: Prednisone for chronic active liver disease: Dose titration, standard dose, and combination with azathioprine compared. Gut 16:876-883, 1975
44. Lenzi M, Johnson PJ, McFarlane IG, Ballardini G, Smith HM, McFarlane GM, Bridger C, Vergani D, Bianchi FB, Williams R: Antibodies to hepatitis C virus in autoimmune liver disease: Evidence for geographical heterogeneity. Lancet 338:277-280, 1991
45. Silva E, Sallie R, Tibbs C, McFarlane I, Johnson P, Williams R: Absence of hepatitis C virus in British patients with type I autoimmune chronic active hepatitis - a polymerase chain reaction and serological study. J Hepatol 19:211-215, 1993
46. Nakatsuji Y, Matsumoto A, Tanaka E, Ogata H, Kiyosuwa K: Detection of chronic hepatitis C virus infection by four diagnostic systems: First-generation and second-generation enzyme-linked immunosorbent assay, second-generation recombinant immunoblot assay and nested polymerase chain reaction analysis. Hepatology 16:300-305, 1992
47. Zein NN, Rakela J, Persing DH: Genotype-dependent serologic reactivities in patients infected with hepatitis C virus in the United States. Mayo Clin Proc 70:449-452, 1995
48. Schalm SW, Ammon HV, Summerskill WHJ: Failure of customary treatment in chronic active liver disease: Causes and management. Ann Clin Res 8:221-227, 1976
49. Czaja AJ, Davis GL, Ludwig J, Taswell HF: Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 4:622-627, 1984